NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
Phase 2
Completed
- Conditions
- Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 124
- Registration Number
- NCT00087139
- Locations
- 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Saint Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸Methodist Medical Center of Illinois, Peoria, Illinois, United States
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase 2
Terminated
- Conditions
- Recurrent MelanomaStage IV Melanoma
- Interventions
- Biological: recombinant fowlpox-TRICOM vaccineOther: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT00087373
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT00087152
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Recurrent Small Cell Lung Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00086827
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00087217
- Locations
- 🇺🇸
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
Not Applicable
Terminated
- Conditions
- Localized Extrahepatic Bile Duct CancerLocalized Gastrointestinal Carcinoid TumorLocalized Resectable Adult Primary Liver CancerAdvanced Adult Primary Liver CancerSmall Intestine LymphomaLocalized Unresectable Adult Primary Liver CancerOvarian SarcomaOvarian Stromal CancerCarcinoma of the AppendixFallopian Tube Cancer
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00087191
- Locations
- 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
Phase 2
Terminated
- Conditions
- Stage IA Non-small Cell Lung CancerStage IB Non-small Cell Lung CancerStage IIA Non-small Cell Lung CancerStage IIB Non-small Cell Lung CancerStage IIIA Non-small Cell Lung Cancer
- Interventions
- Procedure: therapeutic endoscopic surgeryOther: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 110
- Registration Number
- NCT00087269
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
Phase 2
Completed
- Conditions
- Gastrointestinal Stromal TumorRecurrent Adult Soft Tissue SarcomaStage I Adult Soft Tissue SarcomaStage II Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00087074
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 2
Terminated
- Conditions
- Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRefractory Chronic Lymphocytic Leukemia
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00086840
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Recurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell Lymphoma
- Interventions
- Biological: oblimersen sodiumBiological: rituximabBiological: filgrastimBiological: pegfilgrastimOther: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00086944
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States